Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2006

View Archived Issues

DTA-H19: a new DNA-based cancer therapy

7TM Pharma receives milestone payment from research collaboration with P&G

BGC-20-761 improves in vivo cognitive benefits mediated via 5-HT6 antagonism

Spine Wave cleared to begin pilot trial of NuCore Injectable Nucleus

Rexahn partners with University of Maryland in nanomedicine

Nastech Pharmaceutical acquires RNAi program targeting influenza from Galenea

Targeting of IGF-IR and Bcl-2 eradicates androgen-independent prostate cells in vitro

mGluR III agonists: New restorers of neural circuits in Parkinson's disease?

Xanthus Life Sciences changes name to Xanthus Pharmaceuticals

Celtic Pharma licenses IDEA's Transfersome technology and derma pipeline

AP-5346 studied in head and neck cancer

Phase I study assesses safety of gene therapy product AGTC-0106

ZIO-201 begins phase I/II study in sarcoma

Alcon withdraws application to extend European approval of Opatanol

OrthoLogic to acquire certain assets of AzERx

Cyproxan receives Japanese approval for new indication

PEP-005 Topical gel well tolerated in dose-escalation study

In vivo metabolism of new combi-molecule facilitates potent multiple tumor targeting

Indole-3-carbinol and genistein target BRCA1 and BRCA2 genes

LA-12 overcomes cisplatin resistance in ovarian tumors in mice

Novel antiinfective agents disclosed in recent patent literature

Recent patents disclose novel ophthalmic drugs

New melanocortin MC4 receptor ligands prepared and tested by SCRAS

Phase II trial assesses cortisol synthesis inhibitor DIO-902 for type 2 diabetes

European approval for Rotarix

Oracea filed for approval in U.K.

EluSys presents new efficacy data for Anthim anthrax therapeutic

Ampligen plus oseltamivir or zanamivir synergistically inhibits avian influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...